title: New (alternative) temozolomide regimens for the treatment of glioma.
abstract: One barrier to successful treatment of malignant glioma is resistance to alkylating agents such as temozolomide. The cytotoxic activity of temozolomide and other alkylating agents is believed to manifest largely by the formation of O(6)-methylguanine DNA adducts. Consequently, the primary mechanism of resistance to temozolomide is a function of the activity of the DNA repair enzyme O(6)-methylguanine DNA methyltransferase (MGMT). Fortuitously, MGMT is inactivated after each reaction (i.e., suicide enzyme). Therefore, if the rate of DNA alkylation were to outpace the rate of MGMT protein synthesis, the enzyme could, in theory, be depleted. Several studies have shown that prolonged exposure to temozolomide can deplete MGMT activity in blood cells, a process that could potentially increase the antitumor activity of the drug. To date, however, there are limited data demonstrating the depletion of MGMT activity in tumor tissue exposed to temozolomide. A variety of dosing schedules that increase the duration of exposure and the cumulative dose of temozolomide are currently being investigated for the treatment of glioma, with the goal of improving antitumor activity and overcoming resistance. These alternative dosing regimens have been shown to deplete MGMT activity in peripheral blood mononuclear cells, but the regimen that provides the best balance between enhanced antitumor activity and acceptable hematologic toxicity has yet to be determined.
authors.affiliation: Department of Neurooncology, University Clinic of Heidelberg, Heidelberg, Germany. wolfgang.wick@med.uni-heidelberg.de
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Wick
authors.forename: Michael
authors.initials: M
authors.lastname: Platten
authors.forename: Michael
authors.initials: M
authors.lastname: Weller
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000235:genetics; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005910:Glioma / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D019853:O(6)-Methylguanine-DNA Methyltransferase / Q000235:genetics*; D000077204:Temozolomide
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D019853:O(6)-Methylguanine-DNA Methyltransferase; D000077204:Temozolomide
references.citation: Neuro Oncol. 2002 Oct;4(4):261-7
references.pmid: 12356356
references.citation: Oncogene. 2007 Jan 11;26(2):186-97
references.pmid: 16819506
references.citation: N Engl J Med. 2005 Mar 10;352(10):997-1003
references.pmid: 15758010
references.citation: Ann Oncol. 2005 Jun;16(6):942-9
references.pmid: 15870090
references.citation: Neurology. 2004 Jun 8;62(11):2113-5
references.pmid: 15184628
references.citation: J Clin Oncol. 1998 Dec;16(12):3851-7
references.pmid: 9850030
references.citation: Br J Cancer. 2006 Nov 6;95(9):1155-60
references.pmid: 17024124
references.citation: J Clin Oncol. 2008 Sep 1;26(25):4189-99
references.pmid: 18757334
references.citation: N Engl J Med. 2005 Mar 10;352(10):987-96
references.pmid: 15758009
references.citation: J Natl Cancer Inst. 1993 May 5;85(9):704-10
references.pmid: 8478956
references.citation: Curr Med Chem. 2002 Jul;9(13):1285-301
references.pmid: 12052167
references.citation: Neuro Oncol. 2004 Jan;6(1):28-32
references.pmid: 14769137
references.citation: Oncologist. 2006 Feb;11(2):165-80
references.pmid: 16476837
references.citation: Cancer Res. 1999 Feb 15;59(4):793-7
references.pmid: 10029064
references.citation: J Clin Oncol. 2005 Apr 1;23(10):2372-7
references.pmid: 15800329
references.citation: Cancer Res. 1998 Oct 1;58(19):4363-7
references.pmid: 9766665
references.citation: J Neurooncol. 2004 Jul;68(3):275-83
references.pmid: 15332332
references.citation: Mutat Res. 2000 Apr;462(2-3):71-82
references.pmid: 10767619
references.citation: Cancer. 2008 Mar 1;112(5):1139-46
references.pmid: 18246536
references.citation: Br J Cancer. 1992 Feb;65(2):287-91
references.pmid: 1739631
references.citation: J Clin Oncol. 2010 Apr 20;28(12):2051-7
references.pmid: 20308655
references.citation: Prog Nucleic Acid Res Mol Biol. 1995;51:167-223
references.pmid: 7659775
references.citation: N Engl J Med. 2000 Nov 9;343(19):1350-4
references.pmid: 11070098
references.citation: Br J Cancer. 2003 Apr 7;88(7):1004-11
references.pmid: 12671695
references.citation: J Neurooncol. 1994;21(2):135-40
references.pmid: 7861189
references.citation: Clin Cancer Res. 1999 Oct;5(10):2908-17
references.pmid: 10537360
references.citation: Cancer Treat Rev. 1997 Jan;23(1):35-61
references.pmid: 9189180
references.citation: Cancer Res. 2005 Jul 15;65(14):6394-400
references.pmid: 16024643
references.citation: Neurosurgery. 2004 Feb;54(2):349-57; discussion 357
references.pmid: 14744281
references.citation: Int J Oncol. 2003 Mar;22(3):601-8
references.pmid: 12579314
references.citation: Neuro Oncol. 2002 Jan;4(1):39-43
references.pmid: 11772431
references.citation: Proc Natl Acad Sci U S A. 1990 Jan;87(2):686-90
references.pmid: 2405387
references.citation: J Clin Oncol. 2005 Jun 20;23(18):4235-6; author reply 4236
references.pmid: 15961774
references.citation: Mol Cell Biol. 1997 Sep;17(9):5612-9
references.pmid: 9271436
references.citation: J Clin Oncol. 2007 Aug 1;25(22):3357-61
references.pmid: 17664483
references.citation: Clin Cancer Res. 2001 Aug;7(8):2309-17
references.pmid: 11489806
references.citation: J Clin Oncol. 2007 Apr 20;25(12):1470-5
references.pmid: 17442989
references.citation: Strahlenther Onkol. 2005 Jun;181(6):372-7
references.pmid: 15925979
references.citation: Cancer Res. 1987 Nov 15;47(22):5846-52
references.pmid: 3664486
references.citation: J Clin Oncol. 2002 Mar 1;20(5):1375-82
references.pmid: 11870182
references.citation: J Clin Oncol. 1999 Sep;17(9):2762-71
references.pmid: 10561351
references.citation: Br J Cancer. 1994 Mar;69(3):452-6
references.pmid: 8123472
references.citation: J Clin Oncol. 2004 Feb 15;22(4):610-6
references.pmid: 14726505
references.citation: Cancer Res. 1999 May 15;59(10):2402-10
references.pmid: 10344750
references.citation: Cancer Invest. 2008 Apr-May;26(3):269-77
references.pmid: 18317968
references.citation: Int J Cancer. 2000 Nov 1;88(3):469-73
references.pmid: 11054678
references.citation: J Neurooncol. 2007 Aug;84(1):71-7
references.pmid: 17361334
references.citation: Br J Cancer. 2000 Sep;83(5):588-93
references.pmid: 10944597